Biofrontera Enters Material Definitive Agreement; Details Undisclosed

Ticker: BFRIW · Form: 8-K · Filed: Jan 3, 2024 · CIK: 1858685

Complexity: simple

Sentiment: neutral

Topics: material-agreement, corporate-action, disclosure

TL;DR

**Biofrontera signed a big deal, but they're not telling us what it is yet.**

AI Summary

Biofrontera Inc. filed an 8-K on January 3, 2024, reporting an "Entry into a Material Definitive Agreement" on December 29, 2023. While the filing indicates a significant agreement was made, it does not disclose the specific details, parties involved, or financial terms of this agreement. This matters to investors because without the specifics, it's impossible to assess the potential positive or negative impact of this new agreement on Biofrontera's future operations, financial health, or stock value.

Why It Matters

This filing signals a potentially significant business change for Biofrontera Inc., but the lack of specific details leaves investors in the dark about its implications for the company's future performance and stock price.

Risk Assessment

Risk Level: medium — The filing indicates a material agreement without disclosing details, creating uncertainty and potential for future volatility once specifics are revealed.

Analyst Insight

A smart investor would monitor Biofrontera Inc. for subsequent filings or press releases that provide the specific details of this material definitive agreement before making any investment decisions, as the current filing lacks actionable information.

Key Players & Entities

Forward-Looking Statements

FAQ

What was the specific nature of the "Material Definitive Agreement" entered into by Biofrontera Inc. on December 29, 2023?

The 8-K filing indicates an "Entry into a Material Definitive Agreement" but does not provide any specific details about the nature, terms, or parties involved in this agreement.

Why did Biofrontera Inc. file an 8-K regarding this agreement without disclosing its details?

The filing states that the company entered into a material definitive agreement and includes 'Regulation FD Disclosure', which often means they are making information public to avoid selective disclosure, but the specific reasons for not detailing the agreement are not provided within this filing.

What is the significance of the 'Regulation FD Disclosure' item in this 8-K filing?

Regulation FD Disclosure means the company is making certain information public to ensure fair disclosure to all investors, rather than selectively sharing it. In this case, it indicates the company is formally acknowledging the existence of a material agreement, even if the specifics are withheld for now.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on December 29, 2023, which is the date Biofrontera Inc. entered into the material definitive agreement.

What is Biofrontera Inc.'s business address as stated in the filing?

Biofrontera Inc.'s business address is 120 Presidential Way, Suite 330, Woburn, Massachusetts, 01801.

Filing Stats: 823 words · 3 min read · ~3 pages · Grade level 12.4 · Accepted 2024-01-03 17:27:07

Key Financial Figures

Filing Documents

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 120 Presidential Way , Suite 330 Woburn , Massachusetts 01801 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (781) 245-1325 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Market LLC Preferred Stock Purchase Rights The Nasdaq Stock Market LLC Warrants to purchase common stock BFRIW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the "Exchange Act") (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 1.01 Entry into a Material Definitive Agreement On December 29, 2023, Biofrontera, Inc. (the "Company"), entered into a Confidential Settlement Agreement and Mutual Release (the "Release"), dated as of December 27, 2023 and effective as of December 22, 2023, with Maruho Co. Ltd. ("Maruho"), and a Share Transfer Agreement (the "STA" and, together with the Release, the "Settlement Agreement"), dated as of December 27, 2023 and effective as of December 22, 2023, by and among the Company, Maruho, and Maruho Deutschland GmbH. The Settlement Agreement resolves an arbitration proceeding initiated by the Company against Maruho in the International Chamber of Commerce (the "Arbitration") in which the Company alleged certain claims against Maruho concerning the Share Purchase and Transfer Agreement (the "SPA"), dated as of March 25, 2019, referred to in the Settlement Agreement. In the Arbitration, the Company sought, in part, a declaration that it is not obligated to repay $7.3 million of "start-up costs" to Maruho. The Settlement Agreement contains a mutual release whereby each of the Company and Maruho agreed to release and discharge the other party from any and all claims, actions, causes of action, suits, debts, dues, sums of money, accounts, reckonings, bonds, bills, specialties, covenants, contracts, controversies, agreements, promises, variances, trespasses, damages, judgments, extents, executions, claims, and demands whatsoever, in law, admiralty, equity, arbitration or otherwise, which against the other arising from or in connection with or in any manner relating to the SPA, including but not limited to any claims that were or could have been asserted in the Arbitration. Under the Settlement Agreement, the obligations of the Company to i) repay the $7.3 million of "start-up costs" to Maruho, and ii) make certain profit-sharing payments related to the products acquired by the Company pursuant to the SPA were released. In addition, the Company agreed to transfer 5,451,016 shares of stock of Biofrontera AG, a German corporation, to Maruho. This description of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the Release and STA, which are filed within Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference. Item 7.01. Regulation FD Disclosure. On December 29, 2023, the Company entered into the Settlement Agreement as described under Item 1.01 above. The description of the Settlement Agreement under Item 1.01 above is incorporated into this Item 7.01 by reference. Item 9.01 Financial (d) Exhibits . Exhibit Number Description 10.1 Confidential Settlement Agreement and Mutual Release, dated as of December 27, 2023 and eff

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing